



Novel therapy for hypersomnolence patients

Pasiri Sithinamsuwan, M.D.
Phramongkutklo Hospital

13:30-14:00, Friday November 13th, 2020

Disclosures

Speaker/Presenter	Col. Dr. Pasiri Sithinamsuwan, MD. (Phramongkutklo Hospital)
Grant/Research Support	No disclosure
Speaker's Bureau	Teva Pharma (Thailand)
Advisory board members or consultant	Teva Pharma (Thailand)

This presentation is intended for scientific and educational purposes only.

The presentation slide is the sole responsibility of the presenter and not Teva Pharma (Thailand) Co., Ltd.

The presenter DO NOT anticipate discussing the unapproved use of a

Scope

- Hypersomnia
- General principal of hypersomnia management
- A novel wakefulness promoting agent being available in Thailand

Hypersomnia

- Definition
- Diagnostic criteria
- Differential diagnosis

Hypersomnia

Excessive daytime sleepiness

Prevalence

- General population
- 4%-6%

Page 1 / 9

Hypersomnia

- Consequences
- Fair work performance, QoLs, accidents
- Etiologies